Home/Filings/4/0000950170-25-047104

4//SEC Filing

COLUMN GROUP III-A, LP 4

Accession 0000950170-25-047104

CIK 0001824893other

View on SEC.gov Company Profile

Filed

Mar 27, 8:00 PM ET

Accepted

Mar 28, 8:57 PM ET

Size

65.9 KB

Accession

0000950170-25-047104

Insider Transaction Report

Form 4

Period: 2025-03-26

Surrozen, Inc./DESRZN

COLUMN GROUP III GP, LP

10% Owner

Transactions

Expiration (Short)
Series A Common Warrants
2025-03-26−90,897→ 0 total(indirect: By The Column Group III, LP)
Exercise: $15.50→ Common Stock (90,897 underlying)
Expiration (Short)
Series B Common Warrants
2025-03-26−98,870→ 0 total(indirect: By The Column Group III, LP)
Exercise: $14.25→ Common Stock (98,870 underlying)
Expiration (Short)
Series C Common Warrants
2025-03-26−397,773→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $16.00→ Common Stock (397,773 underlying)
Purchase
Series A Common Warrants
2025-03-26+90,897→ 90,897 total(indirect: By The Column Group III, LP)
Exercise: $11.54→ Common Stock (90,897 underlying)
Expiration (Short)
Series D Common Warrants
2025-03-26−352,225→ 0 total(indirect: By The Column Group III, LP)
Exercise: $16.00→ Common Stock (352,225 underlying)
Purchase
Series E Common Warrants
2025-03-26+172,414→ 172,414 total(indirect: By The Column Group Opportunity II, LP)
Exercise: $11.54→ Common Stock (172,414 underlying)
Purchase
Second Tranche Units (Right to Buy)
2025-03-26+517,241→ 517,241 total(indirect: By The Column Group Opportunity II, LP)
Exercise: $11.60→ Common Stock (775,861 underlying)
Purchase
Common Stock
2025-03-26$11.60/sh+323,886$3,757,078→ 704,332 total(indirect: By The Column Group III, LP)
Purchase
Common Stock
2025-03-26$11.60/sh+365,769$4,242,920→ 795,411 total(indirect: By The Column Group III-A, LP)
Purchase
Common Stock
2025-03-26$11.60/sh+344,827$3,999,993→ 344,827 total(indirect: By The Column Group Opportunity III, LP)
Expiration (Short)
Series A Common Warrants
2025-03-26−102,651→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $15.50→ Common Stock (102,651 underlying)
Purchase
Series B Common Warrants
2025-03-26+111,656→ 111,656 total(indirect: By The Column Group III-A, LP)
Exercise: $11.54→ Common Stock (111,656 underlying)
Purchase
Second Tranche Units (Right to Buy)
2025-03-26+485,830→ 485,830 total(indirect: By The Column Group III, LP)
Exercise: $11.60→ Common Stock (728,745 underlying)
Expiration (Short)
Series B Common Warrants
2025-03-26−111,656→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $14.25→ Common Stock (111,656 underlying)
Expiration (Short)
Series D Common Warrants
2025-03-26−397,773→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $16.00→ Common Stock (397,773 underlying)
Purchase
Series E Common Warrants
2025-03-26+182,884→ 182,884 total(indirect: By The Column Group III-A, LP)
Exercise: $11.54→ Common Stock (182,884 underlying)
Purchase
Second Tranche Units (Right to Buy)
2025-03-26+548,653→ 548,653 total(indirect: By The Column Group III-A, LP)
Exercise: $11.60→ Common Stock (822,980 underlying)
Purchase
Series A Common Warrants
2025-03-26+102,651→ 102,651 total(indirect: By The Column Group III-A, LP)
Exercise: $11.54→ Common Stock (102,651 underlying)
Purchase
Series B Common Warrants
2025-03-26+98,870→ 98,870 total(indirect: By The Column Group III, LP)
Exercise: $11.54→ Common Stock (98,870 underlying)
Expiration (Short)
Series C Common Warrants
2025-03-26−352,225→ 0 total(indirect: By The Column Group III, LP)
Exercise: $16.00→ Common Stock (352,225 underlying)
Purchase
Series E Common Warrants
2025-03-26+161,943→ 161,943 total(indirect: By The Column Group III, LP)
Exercise: $11.54→ Common Stock (161,943 underlying)

COLUMN GROUP III-A, LP

10% Owner

Transactions

Expiration (Short)
Series A Common Warrants
2025-03-26−90,897→ 0 total(indirect: By The Column Group III, LP)
Exercise: $15.50→ Common Stock (90,897 underlying)
Purchase
Series A Common Warrants
2025-03-26+102,651→ 102,651 total(indirect: By The Column Group III-A, LP)
Exercise: $11.54→ Common Stock (102,651 underlying)
Purchase
Series B Common Warrants
2025-03-26+98,870→ 98,870 total(indirect: By The Column Group III, LP)
Exercise: $11.54→ Common Stock (98,870 underlying)
Purchase
Series E Common Warrants
2025-03-26+182,884→ 182,884 total(indirect: By The Column Group III-A, LP)
Exercise: $11.54→ Common Stock (182,884 underlying)
Purchase
Second Tranche Units (Right to Buy)
2025-03-26+517,241→ 517,241 total(indirect: By The Column Group Opportunity II, LP)
Exercise: $11.60→ Common Stock (775,861 underlying)
Purchase
Common Stock
2025-03-26$11.60/sh+365,769$4,242,920→ 795,411 total(indirect: By The Column Group III-A, LP)
Expiration (Short)
Series B Common Warrants
2025-03-26−111,656→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $14.25→ Common Stock (111,656 underlying)
Expiration (Short)
Series C Common Warrants
2025-03-26−352,225→ 0 total(indirect: By The Column Group III, LP)
Exercise: $16.00→ Common Stock (352,225 underlying)
Expiration (Short)
Series D Common Warrants
2025-03-26−352,225→ 0 total(indirect: By The Column Group III, LP)
Exercise: $16.00→ Common Stock (352,225 underlying)
Purchase
Series E Common Warrants
2025-03-26+161,943→ 161,943 total(indirect: By The Column Group III, LP)
Exercise: $11.54→ Common Stock (161,943 underlying)
Purchase
Second Tranche Units (Right to Buy)
2025-03-26+485,830→ 485,830 total(indirect: By The Column Group III, LP)
Exercise: $11.60→ Common Stock (728,745 underlying)
Purchase
Second Tranche Units (Right to Buy)
2025-03-26+548,653→ 548,653 total(indirect: By The Column Group III-A, LP)
Exercise: $11.60→ Common Stock (822,980 underlying)
Purchase
Common Stock
2025-03-26$11.60/sh+323,886$3,757,078→ 704,332 total(indirect: By The Column Group III, LP)
Purchase
Common Stock
2025-03-26$11.60/sh+344,827$3,999,993→ 344,827 total(indirect: By The Column Group Opportunity III, LP)
Purchase
Series A Common Warrants
2025-03-26+90,897→ 90,897 total(indirect: By The Column Group III, LP)
Exercise: $11.54→ Common Stock (90,897 underlying)
Expiration (Short)
Series A Common Warrants
2025-03-26−102,651→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $15.50→ Common Stock (102,651 underlying)
Expiration (Short)
Series B Common Warrants
2025-03-26−98,870→ 0 total(indirect: By The Column Group III, LP)
Exercise: $14.25→ Common Stock (98,870 underlying)
Purchase
Series B Common Warrants
2025-03-26+111,656→ 111,656 total(indirect: By The Column Group III-A, LP)
Exercise: $11.54→ Common Stock (111,656 underlying)
Expiration (Short)
Series C Common Warrants
2025-03-26−397,773→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $16.00→ Common Stock (397,773 underlying)
Expiration (Short)
Series D Common Warrants
2025-03-26−397,773→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $16.00→ Common Stock (397,773 underlying)
Purchase
Series E Common Warrants
2025-03-26+172,414→ 172,414 total(indirect: By The Column Group Opportunity II, LP)
Exercise: $11.54→ Common Stock (172,414 underlying)

COLUMN GROUP III, LP

10% Owner

Transactions

Purchase
Common Stock
2025-03-26$11.60/sh+365,769$4,242,920→ 795,411 total(indirect: By The Column Group III-A, LP)
Purchase
Series E Common Warrants
2025-03-26+161,943→ 161,943 total(indirect: By The Column Group III, LP)
Exercise: $11.54→ Common Stock (161,943 underlying)
Purchase
Common Stock
2025-03-26$11.60/sh+323,886$3,757,078→ 704,332 total(indirect: By The Column Group III, LP)
Expiration (Short)
Series A Common Warrants
2025-03-26−90,897→ 0 total(indirect: By The Column Group III, LP)
Exercise: $15.50→ Common Stock (90,897 underlying)
Purchase
Series A Common Warrants
2025-03-26+102,651→ 102,651 total(indirect: By The Column Group III-A, LP)
Exercise: $11.54→ Common Stock (102,651 underlying)
Purchase
Series B Common Warrants
2025-03-26+98,870→ 98,870 total(indirect: By The Column Group III, LP)
Exercise: $11.54→ Common Stock (98,870 underlying)
Purchase
Series B Common Warrants
2025-03-26+111,656→ 111,656 total(indirect: By The Column Group III-A, LP)
Exercise: $11.54→ Common Stock (111,656 underlying)
Expiration (Short)
Series C Common Warrants
2025-03-26−352,225→ 0 total(indirect: By The Column Group III, LP)
Exercise: $16.00→ Common Stock (352,225 underlying)
Expiration (Short)
Series D Common Warrants
2025-03-26−352,225→ 0 total(indirect: By The Column Group III, LP)
Exercise: $16.00→ Common Stock (352,225 underlying)
Purchase
Second Tranche Units (Right to Buy)
2025-03-26+517,241→ 517,241 total(indirect: By The Column Group Opportunity II, LP)
Exercise: $11.60→ Common Stock (775,861 underlying)
Purchase
Common Stock
2025-03-26$11.60/sh+344,827$3,999,993→ 344,827 total(indirect: By The Column Group Opportunity III, LP)
Purchase
Series A Common Warrants
2025-03-26+90,897→ 90,897 total(indirect: By The Column Group III, LP)
Exercise: $11.54→ Common Stock (90,897 underlying)
Expiration (Short)
Series A Common Warrants
2025-03-26−102,651→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $15.50→ Common Stock (102,651 underlying)
Expiration (Short)
Series B Common Warrants
2025-03-26−98,870→ 0 total(indirect: By The Column Group III, LP)
Exercise: $14.25→ Common Stock (98,870 underlying)
Expiration (Short)
Series B Common Warrants
2025-03-26−111,656→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $14.25→ Common Stock (111,656 underlying)
Expiration (Short)
Series C Common Warrants
2025-03-26−397,773→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $16.00→ Common Stock (397,773 underlying)
Expiration (Short)
Series D Common Warrants
2025-03-26−397,773→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $16.00→ Common Stock (397,773 underlying)
Purchase
Series E Common Warrants
2025-03-26+182,884→ 182,884 total(indirect: By The Column Group III-A, LP)
Exercise: $11.54→ Common Stock (182,884 underlying)
Purchase
Series E Common Warrants
2025-03-26+172,414→ 172,414 total(indirect: By The Column Group Opportunity II, LP)
Exercise: $11.54→ Common Stock (172,414 underlying)
Purchase
Second Tranche Units (Right to Buy)
2025-03-26+548,653→ 548,653 total(indirect: By The Column Group III-A, LP)
Exercise: $11.60→ Common Stock (822,980 underlying)
Purchase
Second Tranche Units (Right to Buy)
2025-03-26+485,830→ 485,830 total(indirect: By The Column Group III, LP)
Exercise: $11.60→ Common Stock (728,745 underlying)

Column Group Opportunity III, LP

10% Owner

Transactions

Purchase
Common Stock
2025-03-26$11.60/sh+323,886$3,757,078→ 704,332 total(indirect: By The Column Group III, LP)
Expiration (Short)
Series D Common Warrants
2025-03-26−397,773→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $16.00→ Common Stock (397,773 underlying)
Purchase
Series E Common Warrants
2025-03-26+172,414→ 172,414 total(indirect: By The Column Group Opportunity II, LP)
Exercise: $11.54→ Common Stock (172,414 underlying)
Purchase
Second Tranche Units (Right to Buy)
2025-03-26+517,241→ 517,241 total(indirect: By The Column Group Opportunity II, LP)
Exercise: $11.60→ Common Stock (775,861 underlying)
Purchase
Common Stock
2025-03-26$11.60/sh+365,769$4,242,920→ 795,411 total(indirect: By The Column Group III-A, LP)
Purchase
Common Stock
2025-03-26$11.60/sh+344,827$3,999,993→ 344,827 total(indirect: By The Column Group Opportunity III, LP)
Purchase
Series A Common Warrants
2025-03-26+90,897→ 90,897 total(indirect: By The Column Group III, LP)
Exercise: $11.54→ Common Stock (90,897 underlying)
Purchase
Series A Common Warrants
2025-03-26+102,651→ 102,651 total(indirect: By The Column Group III-A, LP)
Exercise: $11.54→ Common Stock (102,651 underlying)
Expiration (Short)
Series A Common Warrants
2025-03-26−90,897→ 0 total(indirect: By The Column Group III, LP)
Exercise: $15.50→ Common Stock (90,897 underlying)
Expiration (Short)
Series B Common Warrants
2025-03-26−98,870→ 0 total(indirect: By The Column Group III, LP)
Exercise: $14.25→ Common Stock (98,870 underlying)
Expiration (Short)
Series C Common Warrants
2025-03-26−397,773→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $16.00→ Common Stock (397,773 underlying)
Purchase
Series E Common Warrants
2025-03-26+161,943→ 161,943 total(indirect: By The Column Group III, LP)
Exercise: $11.54→ Common Stock (161,943 underlying)
Purchase
Second Tranche Units (Right to Buy)
2025-03-26+485,830→ 485,830 total(indirect: By The Column Group III, LP)
Exercise: $11.60→ Common Stock (728,745 underlying)
Purchase
Second Tranche Units (Right to Buy)
2025-03-26+548,653→ 548,653 total(indirect: By The Column Group III-A, LP)
Exercise: $11.60→ Common Stock (822,980 underlying)
Purchase
Series B Common Warrants
2025-03-26+111,656→ 111,656 total(indirect: By The Column Group III-A, LP)
Exercise: $11.54→ Common Stock (111,656 underlying)
Expiration (Short)
Series C Common Warrants
2025-03-26−352,225→ 0 total(indirect: By The Column Group III, LP)
Exercise: $16.00→ Common Stock (352,225 underlying)
Expiration (Short)
Series D Common Warrants
2025-03-26−352,225→ 0 total(indirect: By The Column Group III, LP)
Exercise: $16.00→ Common Stock (352,225 underlying)
Expiration (Short)
Series A Common Warrants
2025-03-26−102,651→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $15.50→ Common Stock (102,651 underlying)
Purchase
Series B Common Warrants
2025-03-26+98,870→ 98,870 total(indirect: By The Column Group III, LP)
Exercise: $11.54→ Common Stock (98,870 underlying)
Expiration (Short)
Series B Common Warrants
2025-03-26−111,656→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $14.25→ Common Stock (111,656 underlying)
Purchase
Series E Common Warrants
2025-03-26+182,884→ 182,884 total(indirect: By The Column Group III-A, LP)
Exercise: $11.54→ Common Stock (182,884 underlying)

Column Group Opportunity III GP, LP

10% Owner

Transactions

Purchase
Common Stock
2025-03-26$11.60/sh+323,886$3,757,078→ 704,332 total(indirect: By The Column Group III, LP)
Expiration (Short)
Series A Common Warrants
2025-03-26−102,651→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $15.50→ Common Stock (102,651 underlying)
Expiration (Short)
Series B Common Warrants
2025-03-26−98,870→ 0 total(indirect: By The Column Group III, LP)
Exercise: $14.25→ Common Stock (98,870 underlying)
Purchase
Series B Common Warrants
2025-03-26+98,870→ 98,870 total(indirect: By The Column Group III, LP)
Exercise: $11.54→ Common Stock (98,870 underlying)
Expiration (Short)
Series D Common Warrants
2025-03-26−397,773→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $16.00→ Common Stock (397,773 underlying)
Purchase
Series E Common Warrants
2025-03-26+161,943→ 161,943 total(indirect: By The Column Group III, LP)
Exercise: $11.54→ Common Stock (161,943 underlying)
Purchase
Series E Common Warrants
2025-03-26+182,884→ 182,884 total(indirect: By The Column Group III-A, LP)
Exercise: $11.54→ Common Stock (182,884 underlying)
Purchase
Series E Common Warrants
2025-03-26+172,414→ 172,414 total(indirect: By The Column Group Opportunity II, LP)
Exercise: $11.54→ Common Stock (172,414 underlying)
Purchase
Second Tranche Units (Right to Buy)
2025-03-26+485,830→ 485,830 total(indirect: By The Column Group III, LP)
Exercise: $11.60→ Common Stock (728,745 underlying)
Purchase
Second Tranche Units (Right to Buy)
2025-03-26+548,653→ 548,653 total(indirect: By The Column Group III-A, LP)
Exercise: $11.60→ Common Stock (822,980 underlying)
Purchase
Common Stock
2025-03-26$11.60/sh+365,769$4,242,920→ 795,411 total(indirect: By The Column Group III-A, LP)
Purchase
Common Stock
2025-03-26$11.60/sh+344,827$3,999,993→ 344,827 total(indirect: By The Column Group Opportunity III, LP)
Expiration (Short)
Series A Common Warrants
2025-03-26−90,897→ 0 total(indirect: By The Column Group III, LP)
Exercise: $15.50→ Common Stock (90,897 underlying)
Purchase
Series A Common Warrants
2025-03-26+90,897→ 90,897 total(indirect: By The Column Group III, LP)
Exercise: $11.54→ Common Stock (90,897 underlying)
Purchase
Series A Common Warrants
2025-03-26+102,651→ 102,651 total(indirect: By The Column Group III-A, LP)
Exercise: $11.54→ Common Stock (102,651 underlying)
Expiration (Short)
Series B Common Warrants
2025-03-26−111,656→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $14.25→ Common Stock (111,656 underlying)
Purchase
Series B Common Warrants
2025-03-26+111,656→ 111,656 total(indirect: By The Column Group III-A, LP)
Exercise: $11.54→ Common Stock (111,656 underlying)
Expiration (Short)
Series C Common Warrants
2025-03-26−352,225→ 0 total(indirect: By The Column Group III, LP)
Exercise: $16.00→ Common Stock (352,225 underlying)
Expiration (Short)
Series C Common Warrants
2025-03-26−397,773→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $16.00→ Common Stock (397,773 underlying)
Expiration (Short)
Series D Common Warrants
2025-03-26−352,225→ 0 total(indirect: By The Column Group III, LP)
Exercise: $16.00→ Common Stock (352,225 underlying)
Purchase
Second Tranche Units (Right to Buy)
2025-03-26+517,241→ 517,241 total(indirect: By The Column Group Opportunity II, LP)
Exercise: $11.60→ Common Stock (775,861 underlying)

TCG Opportunity III GP, LLC

10% Owner

Transactions

Purchase
Common Stock
2025-03-26$11.60/sh+323,886$3,757,078→ 704,332 total(indirect: By The Column Group III, LP)
Expiration (Short)
Series C Common Warrants
2025-03-26−397,773→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $16.00→ Common Stock (397,773 underlying)
Expiration (Short)
Series D Common Warrants
2025-03-26−397,773→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $16.00→ Common Stock (397,773 underlying)
Purchase
Series E Common Warrants
2025-03-26+172,414→ 172,414 total(indirect: By The Column Group Opportunity II, LP)
Exercise: $11.54→ Common Stock (172,414 underlying)
Purchase
Series E Common Warrants
2025-03-26+161,943→ 161,943 total(indirect: By The Column Group III, LP)
Exercise: $11.54→ Common Stock (161,943 underlying)
Purchase
Common Stock
2025-03-26$11.60/sh+365,769$4,242,920→ 795,411 total(indirect: By The Column Group III-A, LP)
Expiration (Short)
Series A Common Warrants
2025-03-26−90,897→ 0 total(indirect: By The Column Group III, LP)
Exercise: $15.50→ Common Stock (90,897 underlying)
Expiration (Short)
Series B Common Warrants
2025-03-26−98,870→ 0 total(indirect: By The Column Group III, LP)
Exercise: $14.25→ Common Stock (98,870 underlying)
Purchase
Series B Common Warrants
2025-03-26+111,656→ 111,656 total(indirect: By The Column Group III-A, LP)
Exercise: $11.54→ Common Stock (111,656 underlying)
Expiration (Short)
Series D Common Warrants
2025-03-26−352,225→ 0 total(indirect: By The Column Group III, LP)
Exercise: $16.00→ Common Stock (352,225 underlying)
Purchase
Series E Common Warrants
2025-03-26+182,884→ 182,884 total(indirect: By The Column Group III-A, LP)
Exercise: $11.54→ Common Stock (182,884 underlying)
Purchase
Second Tranche Units (Right to Buy)
2025-03-26+548,653→ 548,653 total(indirect: By The Column Group III-A, LP)
Exercise: $11.60→ Common Stock (822,980 underlying)
Purchase
Common Stock
2025-03-26$11.60/sh+344,827$3,999,993→ 344,827 total(indirect: By The Column Group Opportunity III, LP)
Purchase
Series A Common Warrants
2025-03-26+90,897→ 90,897 total(indirect: By The Column Group III, LP)
Exercise: $11.54→ Common Stock (90,897 underlying)
Expiration (Short)
Series A Common Warrants
2025-03-26−102,651→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $15.50→ Common Stock (102,651 underlying)
Purchase
Series A Common Warrants
2025-03-26+102,651→ 102,651 total(indirect: By The Column Group III-A, LP)
Exercise: $11.54→ Common Stock (102,651 underlying)
Purchase
Series B Common Warrants
2025-03-26+98,870→ 98,870 total(indirect: By The Column Group III, LP)
Exercise: $11.54→ Common Stock (98,870 underlying)
Expiration (Short)
Series B Common Warrants
2025-03-26−111,656→ 0 total(indirect: By The Column Group III-A, LP)
Exercise: $14.25→ Common Stock (111,656 underlying)
Expiration (Short)
Series C Common Warrants
2025-03-26−352,225→ 0 total(indirect: By The Column Group III, LP)
Exercise: $16.00→ Common Stock (352,225 underlying)
Purchase
Second Tranche Units (Right to Buy)
2025-03-26+485,830→ 485,830 total(indirect: By The Column Group III, LP)
Exercise: $11.60→ Common Stock (728,745 underlying)
Purchase
Second Tranche Units (Right to Buy)
2025-03-26+517,241→ 517,241 total(indirect: By The Column Group Opportunity II, LP)
Exercise: $11.60→ Common Stock (775,861 underlying)

Footnotes (15)

[F1]Represents a price per unit, consisting of (i) $11.5375 per share of the Issuer's Common Stock and (ii) $0.0625 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP"), The Column Group III-A, LP ("TCG III-A LP") and The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased in the Issuer's private placement on March 24, 2025 (the "2025 Private Placement").
[F10]These Series E Common Warrants are exercisable immediately and will not expire until exercised in full (subject to certain beneficial ownership limitations).
[F11]Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice").
[F12](Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing.
[F13]Consists of (a) 485,830 shares of the Issuer's Common Stock and (b) 242,915 Series E Warrants to purchase shares of the Issuer's Common Stock.
[F14]Consists of (a) 548,653 shares of the Issuer's Common Stock and (b) 274,327 Series E Warrants to purchase shares of the Issuer's Common Stock.
[F15]Consists of (a) 517,241 shares of the Issuer's Common Stock and (b) 258,620 Series E Warrants to purchase shares of the Issuer's Common Stock.
[F2]The amount beneficially owned by the Reporting Persons, has been updated to correct an administrative error in previously reported Form 4s.
[F3]The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
[F4]The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
[F5]The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Members"). TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
[F6]These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.
[F7]These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,
[F8](Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.
[F9]These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement.

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

Surrozen, Inc./DE

CIK 0001824893

→

Entity typeother

IncorporatedDE

Related Parties

filerCIK 0001668085

Filing Metadata

Form type: 4
Filed: Mar 27, 8:00 PM ET
Accepted: Mar 28, 8:57 PM ET
Size: 65.9 KB

View on SEC.gov